Trial abstract · §3
RECONNECT-301 — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Change in the Female Sexual Function Index desire domain score and in the associated distress measure | A statistically significant but numerically small improvement in desire and distress scores | Moderate |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for PT-141 (bremelanotide) from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | 40.0 | 1.3 | RECONNECT pooled |
| Flushing | 20.3 | 0.3 | RECONNECT pooled |
| Injection-site reaction | 13.2 | 8.0 | RECONNECT pooled |
| Headache | 11.3 | 1.9 | RECONNECT pooled |
| Vomiting | 4.8 | 0.3 | RECONNECT pooled |
| Focal hyperpigmentation | 1.2 | 0.0 | RECONNECT pooled; more frequent with repeated dosing and on the face, gingiva and breasts |
| Transient blood-pressure increase | — | — | A mean rise of approximately 6 mmHg systolic peaking at 2–4 hours, with compensatory heart-rate reduction |
| Discontinuation for adverse events | 18.0 | 2.0 | RECONNECT pooled |
Compound Evidence Institute · CEI-TR-0133/3 · https://compoundevidence.com/trials/reconnect-301/results/ · retrieved 30 July 2026